A detailed history of James Hambro & Partners transactions in Eli Lilly & CO stock. As of the latest transaction made, James Hambro & Partners holds 340 shares of LLY stock, worth $261,038. This represents 0.01% of its overall portfolio holdings.

Number of Shares
340
Previous 328 3.66%
Holding current value
$261,038
Previous $296,000 1.69%
% of portfolio
0.01%
Previous 0.01%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$772.14 - $960.02 $9,265 - $11,520
12 Added 3.66%
340 $301,000
Q1 2024

Apr 26, 2024

BUY
$592.2 - $792.28 $194,241 - $259,867
328 New
328 $255,000
Q4 2021

Feb 01, 2022

SELL
$224.85 - $279.04 $411,025 - $510,085
-1,828 Closed
0 $0
Q2 2021

Jul 20, 2021

SELL
$180.55 - $233.54 $18,055 - $23,354
-100 Reduced 5.19%
1,828 $419,000
Q1 2021

Apr 28, 2021

BUY
$164.32 - $212.72 $316,808 - $410,124
1,928 New
1,928 $360,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $730B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track James Hambro & Partners Portfolio

Follow James Hambro & Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of James Hambro & Partners, based on Form 13F filings with the SEC.

News

Stay updated on James Hambro & Partners with notifications on news.